News Quantified

BCRX – biocryst pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range [Yahoo! Finance]

BioCryst Announces Preliminary Full Year 2025 ORLADEYO® (berotralstat) Net Revenue of $601 Million (+37 percent y-o-y), Beating Prior Guidance Range

A Look At BioCryst Pharmaceuticals (BCRX) Valuation As Undervalued Narrative Gains Traction [Yahoo! Finance]

BioCryst to Present at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

-3.2%

BEAT

3.9%

BEAT

16.6%

BEAT

-16.6%

MISS

Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 12

Form 3 BIOCRYST PHARMACEUTICALS For: Jan 01 Filed by: Dullinger Ronald

Form 8-K BIOCRYST PHARMACEUTICALS For: Jan 09

Form 4 BIOCRYST PHARMACEUTICALS For: Dec 19 Filed by: Stonehouse Jon P

Form 4 BIOCRYST PHARMACEUTICALS For: Dec 19 Filed by: Barnes Alane P

Top News Gainers

11/18 Form 4 BIOCRYST PHARMACEUTICALS For: Nov 18 Filed by: Babu Yarlagadda S 19.8%

3/3 Form 4 BIOCRYST PHARMACEUTICALS For: Feb 27 Filed by: LEVIN ALAN G 15.1%

5/29 Form SC 13G BIOCRYST PHARMACEUTICALS Filed by: INTEGRATED CORE STRATEGIES (US) LLC 14.7%

4/9 BioCryst Begins Clinical Trial with Galidesivir for Treatment of Patients with COVID-19 13.5%

9/23 BioCryst Appoints Helen Thackray, M.D., to Board of Directors 12.9%

2/25 Form 4 BIOCRYST PHARMACEUTICALS For: Feb 21 Filed by: Jones Michael L 11.9%

3/13 BioCryst Pharmaceuticals: Multiple Value Drivers With A Coronavirus Kicker [Seeking Alpha] 11.9%

1/26 5 Biotech Stocks to Watch With the Coronavirus Scare [The Motley Fool] 11.1%

3/19 BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 11.0%

4/23 BioCryst feels Gilead's remdesivir pain, down 9% [Seeking Alpha] 10.6%

Top News Decliners

5/20 Form 4 BIOCRYST PHARMACEUTICALS For: May 16 Filed by: STAAB THOMAS R II -52.9%

3/9 BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC. -34.2%

3/10 Form 8-K BIOCRYST PHARMACEUTICALS For: Mar 04 -23.2%

3/16 BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2 -19.7%

4/9 BioCryst stock rallies on start of coronavirus drug study [MarketWatch] -19.0%

12/11 Form 8-K BIOCRYST PHARMACEUTICALS For: Dec 11 -10.4%

1/12 BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference -10.1%

1/27 Why BioCryst Pharmaceuticals Stock Is Jumping Again Today [The Motley Fool] -10.0%

2/25 BioCryst Appoints Alan G. Levin to Board of Directors -9.4%

5/24 Form 4 BIOCRYST PHARMACEUTICALS For: May 22 Filed by: ASELAGE STEVE -9.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day